INO-02

INO-02 is an investigational inhibitor of triggering receptor expressed on myeloid cells like transcript 1 (TREML1, also referred to as TREM1 family) that was being developed by Inotrem for the treatment of acute and chronic inflammatory indications, but whose global development status has been reported as discontinued. As a modulator of the TREM1/TREML1 pathway on myeloid cells, it was intended to dampen excessive inflammatory responses implicated in severe and persistent inflammation-driven diseases. Publicly available information on its precise molecular modality, formulation, dosing route, and specific target indications has not been disclosed, and no active clinical trials or regulatory filings are currently associated with this asset.

Other names

INO 002INO002INO-002